Aim The value of disease‐modifying therapies (such as tafamidis) in patients with
transthyretin amyloid cardiomyopathy (ATTR‐CM) and severe heart failure symptoms has …

Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause
of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non …

The care of systemic amyloidosis has improved dramatically due to improved awareness,
accurate diagnostic tools, the development of powerful prognostic and companion …

We thank Baldovino et al for their interest in our recent article, which demonstrated the long-
term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) …

SUMÁRIO RESUMO EXECUTIVO................................................................................................ 4
LISTA DE SIGLAS E ABREVIAÇÕES.............................................................................. 7 LISTA DE …